P. Loane
Monash University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by P. Loane.
American Journal of Cardiology | 2011
William Wilson; Nick Andrianopoulos; David J. Clark; S. Duffy; A. Brennan; Iwan Harries; G. New; M. Sebastian; P. Loane; Christopher M. Reid; Andrew E. Ajani
The aim was to examine timing, causes, and predictors of death during long-term follow-up after contemporary percutaneous coronary intervention (PCI) using a large multicenter Australian registry. The cohort consisted of 10,682 consecutive patients from the Melbourne Interventional Group registry undergoing PCI (February 2004 through November 2009). For the first time in Australia, long-term mortality rates of a PCI cohort were defined by linkage to the National Death Index database. The cohort (mean age 64 ± 12 years) comprised 75% men, 24% diabetics, 59% with multivessel disease, 4.4% with renal failure, 25% with ST-elevation myocardial infarction (STEMI), 2.5% with cardiogenic shock, and 5.1% with heart failure. Drug-eluting stents (DES) were used in 43% of cases. Mean follow-up was 3.2 ± 0.5 years. In-hospital, 30-day, 12-month, and long-term (3.2 ± 0.5 years) mortalities were 1.6% (80% cardiac), 2.1% (79%), 3.9% (61%), and 8.2% (50%), respectively. Independent predictors of long-term mortality included age (hazard ratio 1.05, 95% confidence interval 1.04 to 1.06), cardiogenic shock (4.58, 3.60 to 5.83), renal failure (3.14, 2.58 to 3.82), previous heart failure (1.97, 1.60 to 2.41), STEMI (1.79, 1.47 to 2.18), peripheral vascular disease (1.72, 1.4 to 2.11), non-STEMI (1.58, 1.32 to 1.90), multivessel disease (1.47, 1.24 to 1.74), current smoking (1.39, 1.12 to 1.71), diabetes (1.36, 1.16 to 1.59), and cerebrovascular disease (1.33, 1.06 to 1.60, p <0.01 for all comparisons). DES deployment appeared protective against late mortality (hazard ratio 0.85, 0.73 to 0.99, p = 0.04); however, after 30 days, there was no difference in mortality rates between those who received a bare metal stent and those who received a DES. In conclusion, different clinical variables such as renal and heart failure predicted long-term mortality after PCI, whereas DES use in this large registry was not associated with late mortality risk.
Journal of the American College of Cardiology | 2013
A. Brennan; Nick Andrianopoulos; S. Duffy; Andrew E. Ajani; David J. Clark; Jeffrey Lefkovits; A. Black; Matthew Brooks; Bryan P. Yan; G. New; P. Loane; L. Roberts; Christopher M. Reid
Background: US guidelines recommend a door-to-balloon time (DTBT) of ≤90 minutes for patients presenting with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). System improvements to reduce DTBT were implemented across the period of this study and included regular peer-based review of results, reductions in system delay through electronic transmission of ECGs from the field and the bypassing of emergency departments.
Catheterization and Cardiovascular Interventions | 2015
Lachlan T Couper; P. Loane; Nick Andrianopoulos; A. Brennan; Shane Nanayakkara; Nitesh Nerlekar; Peter Scott; Anthony Walton; David J. Clark; S. Duffy; Andrew E. Ajani; Christopher M. Reid; James Shaw
To evaluate outcomes of patients undergoing rotational atherectomy (RA) in a multicenter percutaneous coronary intervention (PCI) registry.
Internal Medicine Journal | 2014
A. Brennan; Nick Andrianopoulos; S. Duffy; Christopher M. Reid; David J. Clark; P. Loane; G. New; A. Black; B. Yan; M. Brooks; L. Roberts; E. Carroll; Jeffrey Lefkovits; Andrew E. Ajani
Guidelines for patients with ST‐elevation myocardial infarction include a door‐to‐balloon time (DTBT) of ≤90 min for primary percutaneous coronary intervention.
American Journal of Cardiology | 2018
Jessica O'Brien; Christopher M. Reid; Nick Andrianopoulos; Andrew E. Ajani; David J. Clark; Henry Krum; P. Loane; Melanie Freeman; M. Sebastian; A. Brennan; James Shaw; Anthony M. Dart; S. Duffy
Data from previous studies of patients with heart failure and coronary artery disease suggest that those with higher resting heart rates (HRs) have worse cardiovascular outcomes. We sought to evaluate whether HR immediately before percutaneous coronary intervention (PCI) is an independent predictor for 30-day outcome. We analyzed the outcome of 3,720 patients who had HR recorded before PCI from the Melbourne Interventional Group registry. HR and outcomes were analyzed by quintiles, and secondarily by dichotomizing into <70 or ≥70 beats/min. Patients with cardiogenic shock, intra-aortic balloon pump or inotropic support, and out-of-hospital arrest were excluded. The mean ± SD HR was 70.9 ± 14.7 beats/min. HR by quintile was 55 ± 5, 64 ± 2, 70 ± 1, 77 ± 3, and 93 ± 13 beats/min, respectively. Patients with higher HR were more likely to be women, current smokers, have higher systolic and diastolic blood pressure, atrial fibrillation, recent heart failure, lower ejection fraction, and ST-elevation myocardial infarction as the indication for the PCI (all p ≤0.002). However, rates of treated hypertension, multivessel disease, previous myocardial infarction, PCI, and coronary bypass surgery were lower (all p ≤0.004). Increased HR was associated with higher 30-day mortality (p for trend = 0.04), target vessel revascularization (p for trend = 0.003), and 30-day major adverse cardiac events (MACE) (p for trend = 0.004). In a multivariable analysis, HR was an independent predictor of 30-day MACE (OR 1.21 per quintile; 95% confidence interval (CI): 1.06 to 1.39, p = 0.004). When dichotomized into <70 or ≥70 beats/min, HR independently predicted both 30-day MACE (OR 1.59, 95% CI 1.08 to 2.36, p = 0.02) and 30-day mortality (OR 2.80, 95% CI 1.10 to 7.08, p = 0.03). In conclusion, HR immediately before PCI is an independent predictor of adverse 30-day cardiovascular outcomes.
The Medical Journal of Australia | 2011
Bryan P. Yan; Andrew E. Ajani; David J. Clark; S. Duffy; Nick Andrianopoulos; A. Brennan; P. Loane; Christopher M. Reid
The Medical Journal of Australia | 2006
Henry Krum; Adam Meehan; John Varigos; P. Loane; Baki Billah
Cardiovascular Therapeutics | 2014
Justin A. Cole; A. Brennan; Andrew E. Ajani; Bryan P. Yan; S. Duffy; P. Loane; Christopher M. Reid; M. Yudi; G. New; Alexander Black; James Shaw; David J. Clark; Nick Andrianopoulos
Heart Lung and Circulation | 2011
Dion Stub; William Chan; David J. Clark; Andrew E. Ajani; Nick Andrianopoulos; A. Brennan; P. Loane; Alexander Black; G. New; Jonathan E. Shaw; O. Narayan; Christopher M. Reid; Anthony M. Dart; S. Duffy
Heart Lung and Circulation | 2013
Jonathan E. Shaw; P. Loane; Nick Andrianopoulos; A. Brennan; A. Walton; T. Yip; G. New; David J. Clark; S. Duffy; Christopher M. Reid